Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clagen
- Development stage
- Unknown
- Lead developer
- Cadila Pharmaceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Clagen is a multi-ingredient nutraceutical combination therapy indicated for the management of pain and inflammation in patients with osteoarthritis (OA), particularly of the knee. The formulation consists of four key components: Aflapin (a standardized *Boswellia serrata* extract), native type 2 collagen, Mobilee (a proprietary hyaluronic acid matrix containing polysaccharides and collagen), and CurQlife (a bioavailable curcumin extract). Clagen works through a synergistic mechanism involving the inhibition of pro-inflammatory enzymes such as 5-lipoxygenase (5-LOX) and cyclooxygenase-2 (COX-2), as well as providing structural support to joint cartilage and synovial fluid. Clinical studies have demonstrated its efficacy in reducing Visual Analog Scale (VAS) pain scores and improving joint function and quality of life, positioning it as a potential long-term alternative to traditional non-steroidal anti-inflammatory drugs (NSAIDs) to mitigate risks of gastrointestinal and renal toxicity.
- Brand names
- Clagen
02
Targets
ALOX5 (Arachidonate 5-lipoxygenase)NF-κBPTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Clagen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clagen.